Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers

ABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test produc...

Full description

Autores:
Ruiz Correa, Adriana María
Cuesta González, Fanny
Castaño Arias, Paula Andrea
Correa Cano, Omar de Jesús
Gómez Álvarez, Karina
Jaramillo Montoya, Maria Elena
Tipo de recurso:
Article of investigation
Fecha de publicación:
2015
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/35893
Acceso en línea:
https://hdl.handle.net/10495/35893
https://www.longdom.org/bioequivalence-bioavailability.html
Palabra clave:
Disponibilidad Biológica
Biological Availability
Equivalencia Terapéutica
Therapeutic Equivalency
Cromatografía Líquida de Alta Presión
Chromatography, High Pressure Liquid
Eszopiclona
Eszopiclone
Farmacocinética
Pharmacokinetics
Rights
openAccess
License
https://creativecommons.org/licenses/by/4.0/
id UDEA2_8d2a6b48c667f0ca68ff079b0809a251
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/35893
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
title Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
spellingShingle Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
Disponibilidad Biológica
Biological Availability
Equivalencia Terapéutica
Therapeutic Equivalency
Cromatografía Líquida de Alta Presión
Chromatography, High Pressure Liquid
Eszopiclona
Eszopiclone
Farmacocinética
Pharmacokinetics
title_short Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
title_full Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
title_fullStr Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
title_full_unstemmed Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
title_sort Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
dc.creator.fl_str_mv Ruiz Correa, Adriana María
Cuesta González, Fanny
Castaño Arias, Paula Andrea
Correa Cano, Omar de Jesús
Gómez Álvarez, Karina
Jaramillo Montoya, Maria Elena
dc.contributor.author.none.fl_str_mv Ruiz Correa, Adriana María
Cuesta González, Fanny
Castaño Arias, Paula Andrea
Correa Cano, Omar de Jesús
Gómez Álvarez, Karina
Jaramillo Montoya, Maria Elena
dc.contributor.researchgroup.spa.fl_str_mv Grupo de Estudio e Investigaciones Biofarmacéuticas
dc.subject.decs.none.fl_str_mv Disponibilidad Biológica
Biological Availability
Equivalencia Terapéutica
Therapeutic Equivalency
Cromatografía Líquida de Alta Presión
Chromatography, High Pressure Liquid
Eszopiclona
Eszopiclone
Farmacocinética
Pharmacokinetics
topic Disponibilidad Biológica
Biological Availability
Equivalencia Terapéutica
Therapeutic Equivalency
Cromatografía Líquida de Alta Presión
Chromatography, High Pressure Liquid
Eszopiclona
Eszopiclone
Farmacocinética
Pharmacokinetics
description ABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test product) manufactured by Tecnoquímicas S.A (Cali, Col.) and Imovane® (Reference product) from Sanofi-Aventis Farmacéutica Ltda (Brasil). With this purpose, a single dose, randomized, crossover, with two periods, two sequences and a washout period of one week study was developed. Blood samples were drawn from 0 to 24 hours following the drug administration. Zopiclone plasma levels were determined by HPLC method, validated under the FDA parameters. The 90% confidence intervals for the ratios of the ln AUC0-∞ and ln Cmax means between the Test and Reference product were constructed. The 80/125 rule was used as bioequivalence criterion. The study was conducted in 26 healthy volunteers. The estimated pharmacokinetic parameters for Zopiclone, either for the Test product or Reference product were Cmax 72.815 ± 20.54 ng/mL, 74.315 ± 18.04 ng/mL; AUC0-t 467.297 ± 92.21 ng.h/mL, 460.996 ± 115.81 ng.h/mL, and AUC0-∞ 560.298 ± 118.58 ng.h/ mL, 543.549 ± 136.97 ng.h/mL, respectively. The 90% confidence intervals for the ratio between the averages of ln-transformed data of AUC0-∞ and Cmax were 97.38% - 110.59% and 89.97% - 104.84%, respectively. Conclusion: In the present study of single dose, the Test product, Zopiclone 7.5 mg, meets the Bioequivalence criterion regarding the rate and extent of absorption.
publishDate 2015
dc.date.issued.none.fl_str_mv 2015
dc.date.accessioned.none.fl_str_mv 2023-07-12T16:49:09Z
dc.date.available.none.fl_str_mv 2023-07-12T16:49:09Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.1000246
dc.identifier.issn.none.fl_str_mv 0975-0851
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/35893
dc.identifier.doi.none.fl_str_mv 10.4172/jbb.1000246
dc.identifier.url.spa.fl_str_mv https://www.longdom.org/bioequivalence-bioavailability.html
identifier_str_mv Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.1000246
0975-0851
10.4172/jbb.1000246
url https://hdl.handle.net/10495/35893
https://www.longdom.org/bioequivalence-bioavailability.html
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv J. Bioequivalence. Bioavailab.
dc.relation.citationendpage.spa.fl_str_mv 238
dc.relation.citationissue.spa.fl_str_mv 5
dc.relation.citationstartpage.spa.fl_str_mv 233
dc.relation.citationvolume.spa.fl_str_mv 7
dc.relation.ispartofjournal.spa.fl_str_mv Journal of Bioequivalence and Bioavailability
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
http://creativecommons.org/licenses/by/2.5/co/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 6
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv OMICS Publishing Group
dc.publisher.place.spa.fl_str_mv Hyderabad, India
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/9fbc9b0b-f865-4e98-804f-db4ce7f0d968/download
https://bibliotecadigital.udea.edu.co/bitstreams/8c78dc7b-943e-4777-91b9-4beefcda55cc/download
https://bibliotecadigital.udea.edu.co/bitstreams/97949ca5-a022-45e9-b2e6-a543a3dd2bed/download
https://bibliotecadigital.udea.edu.co/bitstreams/15fdee5b-2c0d-45a1-95bb-c0d82ea9aa9a/download
https://bibliotecadigital.udea.edu.co/bitstreams/25b8b6ba-25a2-4571-a71d-3bc0d68f1fa4/download
bitstream.checksum.fl_str_mv 1646d1f6b96dbbbc38035efc9239ac9c
8a4605be74aa9ea9d79846c1fba20a33
28e74ac17812dc6e97a90e26000190fc
6da29ea006021aa57bc54152a86c011e
c2363943268bbddefa852d0450bbbc44
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052302780071936
spelling Ruiz Correa, Adriana MaríaCuesta González, FannyCastaño Arias, Paula AndreaCorrea Cano, Omar de JesúsGómez Álvarez, KarinaJaramillo Montoya, Maria ElenaGrupo de Estudio e Investigaciones Biofarmacéuticas2023-07-12T16:49:09Z2023-07-12T16:49:09Z2015Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.10002460975-0851https://hdl.handle.net/10495/3589310.4172/jbb.1000246https://www.longdom.org/bioequivalence-bioavailability.htmlABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test product) manufactured by Tecnoquímicas S.A (Cali, Col.) and Imovane® (Reference product) from Sanofi-Aventis Farmacéutica Ltda (Brasil). With this purpose, a single dose, randomized, crossover, with two periods, two sequences and a washout period of one week study was developed. Blood samples were drawn from 0 to 24 hours following the drug administration. Zopiclone plasma levels were determined by HPLC method, validated under the FDA parameters. The 90% confidence intervals for the ratios of the ln AUC0-∞ and ln Cmax means between the Test and Reference product were constructed. The 80/125 rule was used as bioequivalence criterion. The study was conducted in 26 healthy volunteers. The estimated pharmacokinetic parameters for Zopiclone, either for the Test product or Reference product were Cmax 72.815 ± 20.54 ng/mL, 74.315 ± 18.04 ng/mL; AUC0-t 467.297 ± 92.21 ng.h/mL, 460.996 ± 115.81 ng.h/mL, and AUC0-∞ 560.298 ± 118.58 ng.h/ mL, 543.549 ± 136.97 ng.h/mL, respectively. The 90% confidence intervals for the ratio between the averages of ln-transformed data of AUC0-∞ and Cmax were 97.38% - 110.59% and 89.97% - 104.84%, respectively. Conclusion: In the present study of single dose, the Test product, Zopiclone 7.5 mg, meets the Bioequivalence criterion regarding the rate and extent of absorption.COL00494536application/pdfengOMICS Publishing GroupHyderabad, Indiahttps://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian VolunteersArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Disponibilidad BiológicaBiological AvailabilityEquivalencia TerapéuticaTherapeutic EquivalencyCromatografía Líquida de Alta PresiónChromatography, High Pressure LiquidEszopiclonaEszopicloneFarmacocinéticaPharmacokineticsJ. Bioequivalence. Bioavailab.23852337Journal of Bioequivalence and BioavailabilityPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/9fbc9b0b-f865-4e98-804f-db4ce7f0d968/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/8c78dc7b-943e-4777-91b9-4beefcda55cc/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdfRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdfArtículo de investigaciónapplication/pdf1000244https://bibliotecadigital.udea.edu.co/bitstreams/97949ca5-a022-45e9-b2e6-a543a3dd2bed/download28e74ac17812dc6e97a90e26000190fcMD51trueAnonymousREADTEXTRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.txtRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.txtExtracted texttext/plain36185https://bibliotecadigital.udea.edu.co/bitstreams/15fdee5b-2c0d-45a1-95bb-c0d82ea9aa9a/download6da29ea006021aa57bc54152a86c011eMD54falseAnonymousREADTHUMBNAILRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.jpgRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.jpgGenerated Thumbnailimage/jpeg16965https://bibliotecadigital.udea.edu.co/bitstreams/25b8b6ba-25a2-4571-a71d-3bc0d68f1fa4/downloadc2363943268bbddefa852d0450bbbc44MD55falseAnonymousREAD10495/35893oai:bibliotecadigital.udea.edu.co:10495/358932025-03-26 20:13:20.298https://creativecommons.org/licenses/by/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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